Oramed Pharmaceuticals, Inc ORMP

NAS: ORMP | ISIN: US68403P2039   30/04/2025
2,320 USD (-0,43%)
(-0,43%)   30/04/2025

28 april 2025 · Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical · Persbericht

4 maart 2025 · Oramed Pharmaceuticals Issues Letter to Shareholders · Persbericht

26 juni 2024 · Oramed Letter to Shareholders · Persbericht

26 juni 2024 · Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock · Persbericht

20 februari 2024 · Oramed Letter to Shareholders · Persbericht

2 augustus 2023 · Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally · Persbericht

20 juni 2023 · Oramed to Present at the 83rd American Diabetes Association Conference · Persbericht

18 mei 2023 · Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit · Persbericht

15 mei 2023 · Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China · Persbericht

1 mei 2023 · Oramed Appoints Ben Shapiro to its Board of Directors · Persbericht

9 februari 2023 · Oramed Pharmaceuticals Issues Shareholder Update · Persbericht

12 januari 2023 · Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes · Persbericht

4 januari 2023 · Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes · Persbericht

21 december 2022 · Oramed Letter to Shareholders · Persbericht

29 november 2022 · Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism · Persbericht

17 november 2022 · Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH · Persbericht

14 november 2022 · Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea · Persbericht

10 november 2022 · Oramed Reports Third Quarter 2022 Financial Results · Persbericht

9 november 2022 · Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH · Persbericht

7 oktober 2022 · Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine · Persbericht

Mijn selecties